Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

2022-09

DiIorio, Michael

Kennedy, Kevin

Liew, Jean W

Putman, Michael S

Sirotich, Emily

Sattui, Sebastian E

Foster, Gary

Harrison, Carly

Larché, Maggie J

Levine, Mitchell

Moni, Tarin T

Thabane, Lehana

Bhana, Suleman

Costello, Wendy

Grainger, Rebecca

Machado, Pedro M

Robinson, Philip C

Sufka, Paul

Wallace, Zachary S

Yazdany, Jinoos

Gore-Massy, Monique

Howard, Richard A

Kodhek, More A

Lalonde, Nadine

Tomasella, Laura-Ann

Wallace, John

Akpabio, Akpabio

Alpízar-Rodríguez, Deshiré

Beesley, Richard P

Berenbaum, Francis

Bulina, Inita

Chock, Eugenia Yupei

Conway, Richard

Duarte-García, Alí

Duff, Eimear

Gheita, Tamer A

Graef, Elizabeth R

Hsieh, Evelyn

El Kibbi, Lina

Liew, David F L

Lo, Chieh

Nudel, Michal

Singh, Aman Dev

Singh, Jasvinder A

Singh, Namrata

Ugarte-Gil, Manuel F

Hausmann, Jonathan S

Simard, Julia F

Sparks, Jeffrey A

COVID-19

inflammation

patient reported outcome measures

vaccination

Journal Article

http://orcid.org/0000-0001-8230-091X

http://orcid.org/0000-0001-9699-4000

http://orcid.org/0000-0002-7087-8543

http://orcid.org/0000-0002-3945-6828

http://orcid.org/0000-0002-8411-7972

http://orcid.org/0000-0002-3156-3418

http://orcid.org/0000-0002-4920-6494

http://orcid.org/0000-0002-6930-0517

http://orcid.org/0000-0001-8252-7815

http://orcid.org/0000-0003-1679-9745

http://orcid.org/0000-0001-8451-8883

http://orcid.org/0000-0003-3485-0006

http://orcid.org/0000-0003-1728-1999

http://orcid.org/0000-0003-0786-8788

http://orcid.org/0000-0001-5735-9856

http://orcid.org/0000-0002-5556-4618

10.1136/rmdopen-2022-002587

We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

link

RMD open 2022; 8(2): e002587

RMD open